本报告以正大天晴药业集团（Chia Tai Tianqing Pharmaceutical Group，以下简称“正大天晴”或“CTTQ”）为核心调研实体，同时将其置于母公司中国生物制药有限公司（Sino Biopharmaceutical Limited，港股代码：1177.HK，以下简称“中生制药”或“公司”）的整体战略框架下进行全景式剖析。正大天晴作为中生制药最为核心的附属公司，贡献了集团...
Source Link本报告以正大天晴药业集团（Chia Tai Tianqing Pharmaceutical Group，以下简称“正大天晴”或“CTTQ”）为核心调研实体，同时将其置于母公司中国生物制药有限公司（Sino Biopharmaceutical Limited，港股代码：1177.HK，以下简称“中生制药”或“公司”）的整体战略框架下进行全景式剖析。正大天晴作为中生制药最为核心的附属公司，贡献了集团...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.